Actively Recruiting
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
Led by Stanford University · Updated on 2026-04-20
104
Participants Needed
2
Research Sites
152 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.
CONDITIONS
Official Title
Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 30 and 70 years old
- For normal-weight diabetes group: diagnosis of type 2 diabetes with HbA1c between 5.7% and 8%, stable medication or lifestyle regimen for at least 3 months
- For normal-weight diabetes group: BMI between 19 and 24.9 kg/m²
- For normal-weight diabetes group: all diabetes medications allowed except insulin and pioglitazone; stable dose of GLP-1 receptor agonists for 3 months allowed
- For normal-weight diabetes group: stable body weight with no more than 2 kg change over last 3 months
- For normal-weight control group: no diabetes diagnosis, fasting plasma glucose under 100 mg/dL and HbA1c under 5.7%, no history of glucose-lowering medications
- For normal-weight control group: BMI between 19 and 24.9 kg/m²
- For normal-weight control group: stable body weight with no more than 2 kg change over last 3 months
You will not qualify if you...
- Women who are pregnant, planning to become pregnant, or breastfeeding
- Previous use of pioglitazone medication
- Body weight change greater than 2 kg in the last 3 months
- Significant liver disease (ALT over 3 times upper limit of normal)
- Significant kidney disease (creatinine over 1.5 mg/dL)
- History of congestive heart failure or fluid overload
- Uncontrolled high blood pressure (over 160/90 mmHg)
- Diagnosis of cancer in last 3 years except skin cancer
- Chronic inflammatory diseases
- Current use of weight loss medications
- History of bariatric surgery or liposuction
- Use of insulin medication
- Active psychiatric disease or eating disorders
- History of substance abuse
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Stanford University
Palo Alto, California, United States, 94304
Actively Recruiting
2
Stanford University, Clinical and Translational Research Unit (CTRU)
Stanford, California, United States, 94304
Not Yet Recruiting
Research Team
N
Nina Shenoy, BS
CONTACT
A
Alisa Turner, BS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here